MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerBing Li, Gerald Schmit-Bindert, Lihong Fan et al.|Lung Cancer|2013Cited by 178
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysisTao Jiang, Caicun Zhou, Meng Qiao et al.|Cancer Immunology Immunotherapy|2018Cited by 99
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patientsWěi Li, Gerald Schmid‐Bindert, Shengxiang Ren et al.|Lung Cancer|2014Cited by 94
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Pingyang Wang et al.|Signal Transduction and Targeted Therapy|2021Cited by 94
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathwayFei Zhou, Guanghui Gao|Experimental Hematology and Oncology|2023Cited by 82